Proactive research analyst says Shield Therapeutics "in fast growth mode"
News release
by
Shield Therapeutics PLC
London, UK
|
February 13, 2023 08:31 AM Eastern Standard Time
Proactive research analyst John Savin speaks to Thomas Warner at the London studio after releasing his latest report into commercial-stage specialty pharmaceutical company Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF).
Savin says that Shield Therapeutics is "in fast growth mode" after its first full year of trading and gives his take on how he expects the company to perform in 2023.
Contact Details
Proactive UK Ltd
+44 20 7989 0813
